Breaking News Instant updates and real-time market news.

ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

12:07
06/23/18
06/23
12:07
06/23/18
12:07

Array BioPharma announces updated results from Phase 3 BEACON CRC trial

Array BioPharma announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer. The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival for patients treated with the triplet was 8 months and is similar between patients receiving one prior line of therapy and patients receiving two prior lines of therapy. The confirmed overall response rate was 48% and among the 17 patients who received only one prior line of therapy the ORR was 62%. The triple combination was generally well-tolerated with no unexpected toxicities. The most common grade 3 or 4 adverse events seen in at least 10% of patients were fatigue, anemia, increased blood creatine kinase and increased aspartate aminotransferase. The presentation also referenced updated, mature Phase 2 results for the doublet of encorafenib and cetuximab that showed a mOS of 9.3 months, mPFS of 4.2 months and an ORR of 24%. The data cutoff for that analysis was January 2018 with the last patient enrolled in April of 2015. Enrollment in the randomized portion of the BEACON CRC trial is ongoing.

  • 23

    Jun

  • 30

    Jun

  • 30

    Jun

ARRY Array BioPharma
$19.37

-0.19 (-0.97%)

05/10/18
JPMS
05/10/18
NO CHANGE
JPMS
Array BioPharma added to Focus List at JPMorgan
05/10/18
JPMS
05/10/18
NO CHANGE
Target $185
JPMS
Overweight
Array BioPharma added to Analyst Focus List at JPMorgan
JPMorgan analyst Anupam Rama added Array BioPharma (ARRY) to his firm's Analyst Focus List as a growth strategy and reiterates an Overweight rating on the shares. The analyst lowered his price target for the stock to $18 from $19 after taking out MEK + I/O from his model. He believes, however, that Roche's (RHHBY) Phase 3 IMblaze370 trial failure was largely priced in. Rama recommends buying Array at current levels ahead of the "multiple" mid-year pipeline catalysts.
06/15/18
PIPR
06/15/18
NO CHANGE
Target $21
PIPR
Overweight
Array should be bought ahead of June 30 PDUFA, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff is confident in Braftovi plus Mektovi approval in BRAF-mutant melanoma by the June 30 FDA action date. Array BioPharma presented at ASCO Phase III data showing median overall survival of 33.6 months for the combo versus 16.9 months for Zelboraf control, Tenthoff tells investors in a research note. This "best-in-class efficacy and tolerability will differentiate the combo on launch," the analyst contends. He recommends buying Array shares by June 30 and reiterates an Overweight rating on the name with a $21 price target.
06/20/18
CANT
06/20/18
NO CHANGE
Target $24
CANT
Overweight
Array BioPharma shares could have more room to advance, says Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein believes Array BioPharma's combination of binimetinib/encorafenib has the "potential to be best-in-class and take a market-leader position." The FDA action date is June 30. Further, the analyst sees opportunity in BRAF+ CRC based on the safety lead-in portion of the Beacon study, which she believes could expand the potential market, with updated results to be presented on June 23. Goldstein thinks Array shares "could have further room to advance" and keeps an Overweight rating on the name with a $24 price target.

TODAY'S FREE FLY STORIES

IBM

IBM

$144.76

3.64 (2.58%)

15:04
10/16/18
10/16
15:04
10/16/18
15:04
Options
IBM options imply 7.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 21

    Oct

  • 22

    Oct

  • 03

    Mar

BA

Boeing

$367.17

8.36 (2.33%)

15:02
10/16/18
10/16
15:02
10/16/18
15:02
Hot Stocks
Boeing sees air cargo traffic doubling in 20 years »

Boeing projects air cargo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 24

    Oct

CLDR

Cloudera

$15.68

0.44 (2.89%)

15:01
10/16/18
10/16
15:01
10/16/18
15:01
Hot Stocks
Cloudera announces strategic alliance with NEC »

Cloudera announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MNKD

MannKind

$1.90

0.24 (14.46%)

15:00
10/16/18
10/16
15:00
10/16/18
15:00
Hot Stocks
FDA sends warning letter to MannKind over Affrezza marketing »

In a warning letter sent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCK

Crown Holdings

$47.93

1.44 (3.10%)

15:00
10/16/18
10/16
15:00
10/16/18
15:00
Options
Call spread in Crown Holdings in front of earnings »

Call spread in Crown…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ONDK

On Deck Capital

$7.28

0.51 (7.53%)

, JPM

JPMorgan

$108.59

2.25 (2.12%)

14:55
10/16/18
10/16
14:55
10/16/18
14:55
Recommendations
On Deck Capital, JPMorgan analyst commentary  »

Janney Montgomery Scott…

ONDK

On Deck Capital

$7.28

0.51 (7.53%)

JPM

JPMorgan

$108.59

2.25 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 21

    Oct

  • 24

    Oct

  • 06

    Nov

  • 06

    Nov

  • 26

    Feb

OSTK

Overstock.com

$27.11

0.33 (1.23%)

14:50
10/16/18
10/16
14:50
10/16/18
14:50
Hot Stocks
Overstock.com says Customer Day 'strongest' non-Holiday sale in company history »

Overstock.com reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWDP

DowDuPont

$60.29

1.36 (2.31%)

14:50
10/16/18
10/16
14:50
10/16/18
14:50
Options
DowDuPont draws call buyers »

DowDuPont draws call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$341.60

8.49 (2.55%)

14:49
10/16/18
10/16
14:49
10/16/18
14:49
Options
Netflix options imply 14.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 13

    Nov

14:45
10/16/18
10/16
14:45
10/16/18
14:45
General news
Canada Manufacturing Preview »

Canada Manufacturing…

H

Hyatt

$72.79

1.08 (1.51%)

14:42
10/16/18
10/16
14:42
10/16/18
14:42
Recommendations
Hyatt analyst commentary  »

Hyatt to-be-acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

ALLY

Ally Financial

$25.87

-0.22 (-0.84%)

14:40
10/16/18
10/16
14:40
10/16/18
14:40
Options
Ally Financial attracts put buying as shares see relative weakness »

Ally Financial attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

CDNS

Cadence Design

$40.13

0.74 (1.88%)

14:34
10/16/18
10/16
14:34
10/16/18
14:34
Hot Stocks
Cadence Design says Verification Suite enabled for HPC server environments »

Cadence Design Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 22

    Oct

EEM

iShares MSCI Emerging Markets ETF

$40.79

0.95 (2.38%)

14:30
10/16/18
10/16
14:30
10/16/18
14:30
Options
Aggressive call spread opened in iShares Emerging Markets Fund »

Aggressive call spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$36.25

3.81 (11.74%)

14:25
10/16/18
10/16
14:25
10/16/18
14:25
Options
Intelsat call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
10/16/18
10/16
14:25
10/16/18
14:25
Conference/Events
Financial Stability Oversight Council to hold a meeting »

The Council will provide…

WBA

Walgreens Boots Alliance

$75.55

0.83 (1.11%)

, AMZN

Amazon.com

$1,811.22

50.23 (2.85%)

14:23
10/16/18
10/16
14:23
10/16/18
14:23
Periodicals
Walgreens CEO says buyout of AmerisourceBergen possible, Bloomberg reports »

Walgreens Boots Alliance…

WBA

Walgreens Boots Alliance

$75.55

0.83 (1.11%)

AMZN

Amazon.com

$1,811.22

50.23 (2.85%)

CVS

CVS Health

$73.05

0.01 (0.01%)

AET

Aetna

$199.90

0.88 (0.44%)

ABC

AmerisourceBergen

$92.51

2.93 (3.27%)

RAD

Rite Aid

$1.05

-0.005 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

  • 06

    Nov

RP

RealPage

$58.71

2.33 (4.13%)

14:22
10/16/18
10/16
14:22
10/16/18
14:22
Hot Stocks
RealPage pays $3M to settle FTC charges over tenant screening »

RealPage has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

MARA

Marathon Patent Group

$0.62

-0.0034 (-0.55%)

14:18
10/16/18
10/16
14:18
10/16/18
14:18
Hot Stocks
Breaking Hot Stocks news story on Marathon Patent Group »

Merrick D. Okamoto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/16/18
10/16
14:17
10/16/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/16/18
10/16
14:16
10/16/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$220.75

5.47 (2.54%)

14:07
10/16/18
10/16
14:07
10/16/18
14:07
Recommendations
Goldman Sachs analyst commentary  »

JMP Securities sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 26

    Oct

DLTR

Dollar Tree

$86.09

5.11 (6.31%)

, DG

Dollar General

$110.50

4.08 (3.83%)

14:07
10/16/18
10/16
14:07
10/16/18
14:07
Recommendations
Dollar Tree, Dollar General, Amazon.com analyst commentary  »

Reported Icahn stake in…

DLTR

Dollar Tree

$86.09

5.11 (6.31%)

DG

Dollar General

$110.50

4.08 (3.83%)

AMZN

Amazon.com

$1,808.50

47.51 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

CAG

Conagra Brands

$36.10

0.2725 (0.76%)

, PF

Pinnacle Foods

$66.45

0.22 (0.33%)

14:04
10/16/18
10/16
14:04
10/16/18
14:04
Conference/Events
Pinnacle Foods to host special shareholder meeting »

Special Shareholder…

CAG

Conagra Brands

$36.10

0.2725 (0.76%)

PF

Pinnacle Foods

$66.45

0.22 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CRON

Cronos Group

$11.66

-0.07 (-0.60%)

14:00
10/16/18
10/16
14:00
10/16/18
14:00
Options
Cronos short-term calls active as shares see up and down action »

Cronos short-term calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.